Talk:Inclisiran

This is the talk page for discussing improvements to the Inclisiran article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
High	This article has been rated as High-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Inclisiran.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Leads are intended to summarise article content

As this is WP policy/guideline content, the sentence on mechanism of action of this agent, unique to the lead, was reproduced in the main body in a new section. Citations were moved there, with the editing summary noting that one of more might be moved back to the lead, if other editors think necessary. (If their appearance at end of sentence properly indicated that they were all in support of just that sentence, then it is sufficient that they were moved with the sentence into the text.) Then, section titles were edited, to indicate the paragraph following was focused on clinical history, and that further content on the history and science of the agent's discovery would be appropriate in the new section.

On a separate matter, I would note that using a standard infobox field that indicates the "Formula" of siRNA agents are singular rubbish (apologies to those believing and maintaining such). I say this, because such representations are meaningless, and should be replaced by useful information, such as is descriptive of the agent/target sequences at which the therapeutic takes aim. (Or not, it it is too much technical bother. It is understood that this venue is amateur description, and not intended as fully useful content.) Cheers. 2601:246:C700:14C:8135:8ED:FD9A:C2B4 (talk) 23:20, 28 August 2022 (UTC)[reply]

Side effects

Since we don't have a side effects section, I assume we should say that this drug is part of the black triangle scheme in the UK, but I don't have a good source for that. CV9933 (talk) 15:18, 16 April 2024 (UTC)[reply]